These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
419 related articles for article (PubMed ID: 23868516)
1. Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study. Leone F; Artale S; Marino D; Cagnazzo C; Cascinu S; Pinto C; Fornarini G; Tampellini M; Di Fabio F; Sartore-Bianchi A; De Carlis L; Pugliese R; Capussotti L; Gioeni L; Siena S; Aglietta M Cancer; 2013 Oct; 119(19):3429-35. PubMed ID: 23868516 [TBL] [Abstract][Full Text] [Related]
2. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY; Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862 [TBL] [Abstract][Full Text] [Related]
3. Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer. Watanabe K; Kawahara H; Enomoto H; Toyama Y; Akiba T; Yanaga K Anticancer Res; 2013 Sep; 33(9):4029-32. PubMed ID: 24023346 [TBL] [Abstract][Full Text] [Related]
4. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362 [TBL] [Abstract][Full Text] [Related]
5. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362 [TBL] [Abstract][Full Text] [Related]
6. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study. Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151 [TBL] [Abstract][Full Text] [Related]
7. Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Doi T; Boku N; Kato K; Komatsu Y; Yamaguchi K; Muro K; Hamamoto Y; Sato A; Koizumi W; Mizunuma N; Takiuchi H Jpn J Clin Oncol; 2010 Oct; 40(10):913-20. PubMed ID: 20462981 [TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial. Chen HH; Lin JK; Chen JB; Chuang CH; Liu MC; Wang JY; Changchien CR Asia Pac J Clin Oncol; 2018 Feb; 14(1):61-68. PubMed ID: 28906589 [TBL] [Abstract][Full Text] [Related]
9. Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer. Karacetin D; Yalcin B; Okten B; Ozturk S; Maral O; Incekara O J BUON; 2009; 14(4):605-8. PubMed ID: 20148449 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study. Waddell T; Gollins S; Soe W; Valle J; Allen J; Bentley D; Morris J; Lloyd A; Swindell R; Taylor MB; Saunders MP Cancer Chemother Pharmacol; 2011 May; 67(5):1111-7. PubMed ID: 20676676 [TBL] [Abstract][Full Text] [Related]
11. [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer]. Diao C; Cheng RC; Zhang JM; Wei XP; Su YJ; Liu QY; Xu JB Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):147-50. PubMed ID: 18646702 [TBL] [Abstract][Full Text] [Related]
12. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795 [TBL] [Abstract][Full Text] [Related]
13. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. Schmoll HJ; Cartwright T; Tabernero J; Nowacki MP; Figer A; Maroun J; Price T; Lim R; Van Cutsem E; Park YS; McKendrick J; Topham C; Soler-Gonzalez G; de Braud F; Hill M; Sirzén F; Haller DG J Clin Oncol; 2007 Jan; 25(1):102-9. PubMed ID: 17194911 [TBL] [Abstract][Full Text] [Related]
14. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167 [TBL] [Abstract][Full Text] [Related]
15. Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients. Coskun U; Buyukberber S; Yaman E; Uner A; Er O; Ozkan M; Dikilitas M; Oguz M; Yildiz R; B DY; Kaya AO; Benekli M Neoplasma; 2008; 55(1):65-70. PubMed ID: 18190244 [TBL] [Abstract][Full Text] [Related]
16. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Kim C; Lee JL; Ryu MH; Chang HM; Kim TW; Lim HY; Kang HJ; Park YS; Ryoo BY; Kang YK Invest New Drugs; 2011 Apr; 29(2):366-73. PubMed ID: 19997960 [TBL] [Abstract][Full Text] [Related]
17. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Wong R; Cunningham D; Barbachano Y; Saffery C; Valle J; Hickish T; Mudan S; Brown G; Khan A; Wotherspoon A; Strimpakos AS; Thomas J; Compton S; Chua YJ; Chau I Ann Oncol; 2011 Sep; 22(9):2042-2048. PubMed ID: 21285134 [TBL] [Abstract][Full Text] [Related]
18. [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer]. Zhao WY; Chen DY; Qi Q Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):295-8. PubMed ID: 21575503 [TBL] [Abstract][Full Text] [Related]
19. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053 [TBL] [Abstract][Full Text] [Related]
20. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. Haller DG; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Gilberg F; Rittweger K; Schmoll HJ J Clin Oncol; 2011 Apr; 29(11):1465-71. PubMed ID: 21383294 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]